Why Grail Could Be the Sleeper Stock Everyone's About to Notice

Grail, a leader in multi-cancer early detection (MCED) testing, could be poised for significant growth as its Galleri test shows promising clinical trial results. The company awaits FDA approval and potential insurance reimbursement, which could unlock a $50 billion market opportunity. However, the stock remains high-risk due to unprofitability and competition from larger players.